Search hospitals
>
New Jersey
>
Newark
Newark Beth Israel Medical Center
Claim this profile
Newark, New Jersey 07112
Global Leader in Breast Cancer
Global Leader in Brain Tumor
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Leukemia
388 reported clinical trials
22 medical researchers
Summary
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Brain Tumor, Cancer, Lung Cancer, Leukemia and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 540 conditions. There are 22 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Mridula George, MD.
Area of expertise
Breast Cancer
Newark Beth Israel Medical Center has run 56 trials for Breast Cancer. Some of their research focus areas include:
Brain Tumor
Newark Beth Israel Medical Center has run 33 trials for Brain Tumor. Some of their research focus areas include:
Top PIs
Teena Bhatla
Newark Beth Israel Medical Center
6 years of reported clinical research
Howard S. Hochster
Rutgers Cancer Institute of New Jersey
6 years of reported clinical research
Missak Haigentz, MD
Rutgers Cancer Institute of New Jersey
4 years of reported clinical research
Mridula George, MD
Rutgers Cancer Institute of New Jersey
2 years of reported clinical research
Clinical Trials running at Newark Beth Israel Medical Center
Breast Cancer
Brain Tumor
Lung Cancer
Testicular cancer
Colon Cancer
Wilms Tumor
Cancer
Breast cancer
Heart Disease
Heart Failure
Fluoropyrimidine Dose-Adjustment
for Colorectal Cancer
To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.
Recruiting
3 awards
Phase 4
2 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting
2 awards
Phase 3
8 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Beth Israel Medical Center?
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Brain Tumor, Cancer, Lung Cancer, Leukemia and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 540 conditions. There are 22 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Mridula George, MD.
Where is Newark Beth Israel Medical Center located?
The Newark Beth Israel Medical Center is located at 201 Lyons Ave, Newark, NJ 07112.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Newark Beth Israel Medical Center, contact the billing department at 973-926-6517. For insurance inquiries, refer to the hospital's phone directory for a dedicated insurance line. Uninsured and underinsured patients meeting specific income and asset criteria may be eligible for the New Jersey Hospital Care Payment Assistance Program (Charity Care).
What insurance does Newark Beth Israel Medical Center accept?
Newark Beth Israel Medical Center, part of RWJBarnabas Health, accepts a wide range of insurance plans including but not limited to Blue Cross/Blue Shield, Commonwealth Care, Harvard Pilgrim Health Care, Neighborhood Health Plan, Mass Health/Medicaid, Medicare, Tufts, and most commercial insurances. They also provide services to patients without insurance. For a detailed list of accepted insurance plans, refer to the RWJBarnabas Health Contracted Health Insurers and Networks list. Note: It's crucial to verify with your physician if they participate in the same insurance plans as the hospital.
What awards or recognition has Newark Beth Israel Medical Center received?
Newark Beth Israel Medical Center is celebrated as one of the World's Best Hospitals by Newsweek for five consecutive years, making it one of seven New Jersey hospitals to achieve this distinction. It has earned the American Heart Association's Get With The Guidelines Gold Award for Heart Failure and Resuscitation. Additionally, it has received the American College of Cardiology's Performance Achievement Award for Cardiac Care.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.